ALK and neuroblastoma: Stratifying eligible neuroblastoma patients for ALK.CAR‐T therapy could use the ALK genetic status and expression levels as a biomarker; nonetheless, the majority of neuroblastoma patients could benefit from this combination therapy irrespective of their ALK genetic status.